US Stock MarketDetailed Quotes
NBSE NeuBase Therapeutics
- 0.3780
- 0.00000.00%
Close May 10 16:00 ET
1.42MMarket Cap-55P/E (TTM)
0.0000High0.0000Low0Volume0.0000Open0.3780Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)3.75MShares4.800052wk High0.16P/B1.26MFloat Cap0.360052wk Low--Dividend TTM3.32MShs Float400.0000Historical High--Div YieldTTM0.00%Amplitude0.3600Historical Low--Avg Price1Lot Size
About NeuBase Therapeutics Company
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Company Profile
SymbolNBSE
Company NameNeuBase Therapeutics
CEOMr. Todd P. Branning
MarketNASDAQ
Employees37
Securities TypeOrdinary Shares
Fiscal Year Ends09-30
Company Executives
- Name
- Position
- Salary
- Todd P. Branning
- Interim Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer
- 819.02K
- Dr. Dov A. Goldstein, M.D.
- Chairman of the Board
- 74.42K
- Dr. Dietrich A. Stephan, PhD
- Director
- 1.15M
- Eric I. Richman
- Independent Director
- 68.38K
- Dr. Franklyn G Prendergast, M.D.,PhD
- Independent Director
- 68.29K
- Gerald J. McDougall
- Independent Director
- 59.79K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg